Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer.

Autor: de M Rêgo JF; Instituto do Cancer do Estado de São Paulo - Adress: Dr Arnaldo Av, 251 - Sao Paulo/SP, 01246-000, Brazil.; Universidade Federal do Rio Grande do Norte - Adress: Nilo Peçanha Av, 620 - Natal/RN, 59012-300, Brazil.; Liga NorteRiograndense Contra o Cancer - Adress: Miguel Castro Av, 1355 - Natal/RN, 59075-740, Brazil., de Medeiros RSS; Universidade de Sao Paulo - Adress: Dr Ovídio Pires de Campos St, 225 - Sao Paulo/SP, 05403-010, Brazil., Braghiroli MI; Instituto do Cancer do Estado de São Paulo - Adress: Dr Arnaldo Av, 251 - Sao Paulo/SP, 01246-000, Brazil.; Hospital Sirio Libanês - Adress: Dona Adma Jafet St, 115 - Sao Paulo/SP, 01308-050, Brazil., Galvão B; Instituto do Cancer do Estado de São Paulo - Adress: Dr Arnaldo Av, 251 - Sao Paulo/SP, 01246-000, Brazil.; Hospital Sirio Libanês - Adress: Dona Adma Jafet St, 115 - Sao Paulo/SP, 01308-050, Brazil., Neto JEB; Instituto do Cancer do Estado de São Paulo - Adress: Dr Arnaldo Av, 251 - Sao Paulo/SP, 01246-000, Brazil.; Hospital Sirio Libanês - Adress: Dona Adma Jafet St, 115 - Sao Paulo/SP, 01308-050, Brazil., Munhoz RR; Instituto do Cancer do Estado de São Paulo - Adress: Dr Arnaldo Av, 251 - Sao Paulo/SP, 01246-000, Brazil.; Hospital Sirio Libanês - Adress: Dona Adma Jafet St, 115 - Sao Paulo/SP, 01308-050, Brazil., Guerra J; Instituto Adolfo Lutz - Adress: Dr Arnaldo Av, 355 - Sao Paulo/SP, 01246-000, Brazil., Nonogaki S; Instituto Adolfo Lutz - Adress: Dr Arnaldo Av, 355 - Sao Paulo/SP, 01246-000, Brazil., Kimura L; Instituto Adolfo Lutz - Adress: Dr Arnaldo Av, 355 - Sao Paulo/SP, 01246-000, Brazil., Pfiffer TE; Instituto do Cancer do Estado de São Paulo - Adress: Dr Arnaldo Av, 251 - Sao Paulo/SP, 01246-000, Brazil.; Hospital Sirio Libanês - Adress: Dona Adma Jafet St, 115 - Sao Paulo/SP, 01308-050, Brazil., de Castro G Jr; Instituto do Cancer do Estado de São Paulo - Adress: Dr Arnaldo Av, 251 - Sao Paulo/SP, 01246-000, Brazil.; Hospital Sirio Libanês - Adress: Dona Adma Jafet St, 115 - Sao Paulo/SP, 01308-050, Brazil., Hoff PM; Instituto do Cancer do Estado de São Paulo - Adress: Dr Arnaldo Av, 251 - Sao Paulo/SP, 01246-000, Brazil.; Hospital Sirio Libanês - Adress: Dona Adma Jafet St, 115 - Sao Paulo/SP, 01308-050, Brazil., Filho DR; Instituto do Cancer do Ceara - Adress: Papi Júnior St - Fortaleza/CE, 60351-010, Brazil., Costa FP; Hospital Sirio Libanês - Adress: Dona Adma Jafet St, 115 - Sao Paulo/SP, 01308-050, Brazil., Riechelmann RP; Instituto do Cancer do Estado de São Paulo - Adress: Dr Arnaldo Av, 251 - Sao Paulo/SP, 01246-000, Brazil.; Hospital Sirio Libanês - Adress: Dona Adma Jafet St, 115 - Sao Paulo/SP, 01308-050, Brazil.
Jazyk: angličtina
Zdroj: Ecancermedicalscience [Ecancermedicalscience] 2017 Sep 11; Vol. 11, pp. 767. Date of Electronic Publication: 2017 Sep 11 (Print Publication: 2017).
DOI: 10.3332/ecancer.2017.767
Abstrakt: Background: Small cell lung cancer (SCLC) and high-grade extrapulmonary neuroendocrine carcinomas (EPNEC) share similar histopathological features and treatment, but outcomes may differ. We evaluated in our study the expression of biomarkers associated with response rate (RR) to chemotherapy and overall survival (OS) for these entities.
Materials and Methods: This is a multicentre retrospective analysis of advanced EPNEC and SCLC patients treated with platinum-based chemotherapy. Paraffin-embedded tumour samples were reviewed by a single pathologist and tested for immunohistochemistry (IHC) expression of Ki-67, ERCC1, Bcl-2, and Lin28a. All images were evaluated by the same radiologist and RR was determined by RECIST 1.1.
Results: From July, 2006 to July, 2014, 142 patients were identified, being 82 (57.7%) SCLC and 60 (42.3%) EPNEC. Clinical characteristics and median Ki-67 (SCLC: 60%; EPNEC: 50%; p = 0.86) were similar between the groups. RR was higher for SCLC patients (86.8% versus 44.6%; p<0.001), but median OS was similar (10.3 months in SCLC and 11.1 months in EPNEC; HR 0.69, p = 0.07). Bcl-2 expression was higher in SCLC patients (46.3% versus 28.3%, p = 0.03) and was associated with worse prognosis in EPNEC (median OS 8.0 months versus 14.7 months; HR 0.47, p = 0.02).
Conclusion: EPNEC patients presented inferior RR to platinum-based chemotherapy than SCLC but tended to live longer. Neither ERCC1, Lin28, or Ki-67 were prognostic or predictive for RR in EPNEC or SCLC. High Bcl-2 expression was associated with poor prognosis in EPNEC patients.
Databáze: MEDLINE
Externí odkaz: